Cardiovascular Systems (CSII) 10-K 24 Aug 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2017	Aug. 18, 2017	Dec. 31, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Cardiovascular Systems Inc
Entity Central Index Key	1,180,145
Document Type	10-K
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Public Float			$ 765.8
Entity Common Stock, Shares Outstanding		32,991,788

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Current assets
Cash and cash equivalents	$ 107,912	$ 60,638
Accounts receivable, net	28,472	23,128
Inventories	16,897	17,440
Marketable securities	704	684
Prepaid expenses and other current assets	5,074	2,992
Total current assets	159,059	104,882
Property and equipment, net	29,696	32,471
Patents, net	5,056	5,013
Other assets	129	40
Total assets	193,940	142,406
Current liabilities
Accounts payable	10,736	8,506
Accrued expenses	30,236	26,993
Total current liabilities	40,972	35,499
Long-term liabilities
Financing obligation	21,100	0
Deferred revenue	10,000	0
Other liabilities	3,479	6,010
Total liabilities	75,551	41,509
Commitments and contingencies
Common stock, $0.001 par value at June 30, 2017 and 2016; authorized 100,000,000 common shares at June 30, 2017 and 2016; issued and outstanding 32,849,563 at June 30, 2017 and 32,792,497 at June 30, 2016	33	33
Additional paid in capital	447,559	428,235
Accumulated other comprehensive income	100	40
Accumulated deficit	(329,303)	(327,411)
Total stockholders’ equity	118,389	100,897
Total liabilities and stockholders’ equity	$ 193,940	$ 142,406

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Jun. 30, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,849,563	32,792,497
Common stock, shares outstanding	32,849,563	32,792,497

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net revenues	$ 204,906	$ 178,184	$ 181,544
Cost of goods sold	39,441	35,421	39,520
Gross profit	165,465	142,763	142,024
Expenses:
Selling, general and administrative	144,096	162,542	143,684
Research and development	22,911	25,934	30,977
Restructuring	0	2,364	0
Legal settlement	0	8,000	0
Total expenses	167,007	198,840	174,661
Loss from operations	(1,542)	(56,077)	(32,637)
Other (income) and expense, net	164	(145)	71
Loss before income taxes	(1,706)	(55,932)	(32,708)
Provision for income taxes	86	92	114
Net loss	$ (1,792)	$ (56,024)	$ (32,822)
Net loss per common share:
Basic and diluted (in usd per share)	$ (0.06)	$ (1.72)	$ (1.04)
Weighted average common shares used in computation:
Basic and diluted (in shares)	32,373,709	32,537,621	31,547,711

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss Statement - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (1,792)	$ (56,024)	$ (32,822)
Other comprehensive income (loss):
Unrealized gain on available for sale securities	66	20	90
Adjustment for net gain realized and included in interest and other, net	(6)	(70)	0
Total change in unrealized gain (loss) on available for sale securities	60	(50)	90
Comprehensive loss	$ (1,732)	$ (56,074)	$ (32,732)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at beginning of period (in shares) at Jun. 30, 2014		31,084,742
Balance at beginning of period at Jun. 30, 2014	$ 152,055,000	$ 31,000	$ 390,589,000	$ 0	$ (238,565,000)
Stock-based compensation related to restricted stock awards, net (in shares)		469,575
Stock-based compensation related to restricted stock awards, net	14,089,000	$ 1,000	14,088,000
Exercise of stock options and warrants (in shares)		222,937
Exercise of stock options and warrants	2,152,000	$ 0	2,152,000
Employee stock purchase plan activity (in shares)		120,870
Employee stock purchase plan activity	3,871,000		3,871,000
Unrealized gain on marketable securities	90,000	$ 0	0	90,000	0
Net gain reclassified from accumulated other comprehensive income	0
Net loss	(32,822,000)				(32,822,000)
Balance at end of period (in shares) at Jun. 30, 2015		31,898,124
Balance at end of period at Jun. 30, 2015	139,435,000	$ 32,000	410,700,000	90,000	(271,387,000)
Stock-based compensation related to restricted stock awards, net (in shares)		557,756
Stock-based compensation related to restricted stock awards, net	11,986,000	$ 1,000	11,985,000
Exercise of stock options and warrants (in shares)		87,817
Exercise of stock options and warrants	1,006,000		1,006,000
Employee stock purchase plan activity (in shares)		248,800
Employee stock purchase plan activity	4,544,000		4,544,000
Unrealized gain on marketable securities	20,000			20,000
Net gain reclassified from accumulated other comprehensive income	(70,000)			(70,000)
Net loss	(56,024,000)				(56,024,000)
Balance at end of period (in shares) at Jun. 30, 2016		32,792,497
Balance at end of period at Jun. 30, 2016	100,897,000	$ 33,000	428,235,000	40,000	(327,411,000)
Stock-based compensation related to restricted stock awards, net (in shares)		(635,018)
Stock-based compensation related to restricted stock awards, net	9,412,000	$ 0	9,412,000
Exercise of stock options and warrants (in shares)		515,164
Exercise of stock options and warrants	5,262,000		5,362,000		(100,000)
Employee stock purchase plan activity (in shares)		176,920
Employee stock purchase plan activity	4,550,000		4,550,000
Unrealized gain on marketable securities	66,000			66,000
Net gain reclassified from accumulated other comprehensive income	(6,000)			(6,000)
Net loss	(1,792,000)				(1,792,000)
Balance at end of period (in shares) at Jun. 30, 2017		32,849,563
Balance at end of period at Jun. 30, 2017	$ 118,389,000	$ 33,000	$ 447,559,000	$ 100,000	$ (329,303,000)

Consolidated Statements of Cha7

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Lower range of exercise of stock options and warrants (in usd per share)	$ 7.90	$ 7.90	$ 5.01
Upper range of exercise of stock options and warrants (in usd per share)	12.19	12.37	$ 12.37
Issuance costs
Common Stock
Lower range of exercise of stock options and warrants (in usd per share)	7.90	7.90	$ 5.01
Upper range of exercise of stock options and warrants (in usd per share)	12.19	12.37	$ 12.37
Issuance costs
Additional Paid In Capital
Lower range of exercise of stock options and warrants (in usd per share)	7.90	7.90	$ 5.01
Upper range of exercise of stock options and warrants (in usd per share)	$ 12.19	$ 12.37	$ 12.37
Issuance costs

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (1,792)	$ (56,024)	$ (32,822)
Adjustments to reconcile net loss to net cash used in operations
Depreciation of property and equipment	3,917	3,686	2,150
Provision for doubtful accounts (including note receivable)	465	725	1,121
Amortization of patents	218	231	171
Write-off of patent costs	733	168	43
Loss on disposal of property and equipment	158	170	121
Stock-based compensation	10,354	12,977	14,718
Other	138	0	0
Changes in assets and liabilities
Accounts receivable	(5,809)	7,327	(10,568)
Inventories	543	(3,474)	(1,076)
Prepaid expenses and other assets	(1,823)	728	(1,183)
Accounts payable	1,761	(970)	581
Accrued expenses and other liabilities	725	10,873	4,387
Deferred revenue	10,000	0	0
Net cash provided by (used in) operations	19,588	(23,583)	(22,357)
Cash flows from investing activities
Expenditures for property and equipment	(981)	(3,818)	(20,325)
Issuance of convertible note receivable	0	(350)	0
Purchases of marketable securities	0	(37)	(2,112)
Sales of marketable securities	46	1,249	365
Costs incurred in connection with patents	(844)	(813)	(955)
Net cash used in investing activities	(1,779)	(3,769)	(23,027)
Cash flows from financing activities
Proceeds from the employee stock purchase plan	3,254	3,142	2,882
Exercise of stock options	5,263	1,006	2,152
Payments on borrowings	0	0	(2,400)
Proceeds from financing	20,944	0	0
Other	4	0	0
Net cash provided by financing activities	29,465	4,148	2,634
Net change in cash and cash equivalents	47,274	(23,204)	(42,750)
Cash and cash equivalents
Beginning of period	60,638	83,842	126,592
End of period	107,912	60,638	83,842
Noncash investing and financing activities
Change in equipment included in accounts payable	(319)	(374)	(469)
Change in patent costs included in accounts payable	(150)	87	(52)
Supplemental cash flow information
Interest paid	$ 500	$ 0	$ 23

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Company Description Cardiovascular Systems, Inc. (the “Company”) was incorporated as Replidyne, Inc. (“Replidyne”) in Delaware in 2000 . On February 25, 2009, Replidyne completed its business combination with Cardiovascular Systems, Inc., a Minnesota corporation, in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 3, 2008. At the effective time of the merger, Replidyne changed its name to Cardiovascular Systems, Inc. The Company develops, manufactures and markets devices for the treatment of vascular diseases. The Company’s peripheral arterial disease (“PAD”) products, the Diamondback 360 ® Peripheral Orbital Atherectomy System (“OAS”) and the Stealth 360° ® Peripheral OAS, are catheter-based platforms capable of treating a broad range of plaque types, including calcified plaque, in leg arteries both above and below the knee, and address many of the limitations associated with other surgical, catheter and pharmacological treatment alternatives. These devices use smaller access sheaths that can provide procedural benefits and allow physicians to treat PAD patients in a variety of vessel sizes, including the small and tortuous vessels located below the knee through alternative access sites in the ankle and foot as well as in the groin. In October 2013, the Company received premarket approval from the U.S. Food and Drug Administration (“FDA”) to market the Diamondback 360 ® Coronary OAS as a treatment for severely calcified coronary arteries. In March 2017, the Company received approval from the FDA to market the Diamondback 360 ® Coronary OAS Micro Crown. The Coronary OAS Micro Crown is the only atherectomy device designed to treat both pilot tight, calcific lesions and treat 2.5 to 4mm vessels with a single device. The Company is currently selling only in the United States. In November 2016, the Company signed an exclusive distribution agreement with Medikit Co., Ltd. (“Medikit”) to sell its Diamondback 360 ® Coronary and Peripheral OAS in Japan. In March 2017, the Company received approval from Japan’s Ministry of Health, Labor and Welfare for its Diamondback 360 ® Coronary OAS Micro Crown. Pending reimbursement approval, Japan would become the first international market for any of the Company’s products. The Company is currently evaluating options for additional international markets to expand the coronary and peripheral opportunities. Principles of Consolidation The consolidated balance sheets and statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows include the accounts of the Company and its wholly-owned subsidiary, after elimination of all intercompany transactions and accounts. Cash and Cash Equivalents The Company considers all money market funds and other investments purchased with an original maturity of three months or less to be cash and cash equivalents. Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required. The Company maintains an allowance for doubtful accounts, which is an estimate regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Provisions for the allowance for doubtful accounts attributed to bad debt are recorded in general and administrative expenses. The following table shows the allowance for doubtful accounts activity: Amount Balances at June 30, 2014 $ 451 Provision for doubtful accounts 1,121 Write-offs (135 ) Balance at June 30, 2015 1,437 Provision for doubtful accounts 375 Write-offs (1,100 ) Balance at June 30, 2016 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 $ 864 Inventories Inventories are stated at the lower of cost or market with cost determined on a first-in, first-out method of valuation. The establishment of inventory allowances for excess and obsolete inventories is based on estimated exposure on specific inventory items. We write down our inventories as we become aware of any situation where the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions. Property and Equipment Property and equipment is carried at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over estimated useful lives of 40 years for the building; five to seven years for production equipment and furniture and fixtures; three years for computer equipment and software; and the shorter of their estimated useful lives or the lease term for leasehold improvements. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. All other expenditures for renewals and betterments are capitalized. The assets and related depreciation accounts are adjusted for property retirements and disposals with the resulting gains or losses included in the consolidated statement of operations. Patents The capitalized costs incurred to obtain patents are amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years. The recoverability of capitalized patent costs is dependent upon the Company’s ability to derive revenue-producing products from such patents or the ultimate sale or licensing of such patent rights. Patent recoverability is regularly reviewed and any patents that are abandoned are written off at the time of abandonment. Long-Lived Assets The Company regularly evaluates the carrying value of long-lived assets for events or changes in circumstances that indicate that the carrying amount may not be recoverable or that the remaining estimated useful life should be changed. An impairment loss is recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset’s carrying value over its fair value. Operating Leases The Company leases its Texas manufacturing facilities under an operating lease agreement. The lease contains rent escalation clauses for which the lease expense is recognized on a straight-line basis over the lease term. Rent expense that is recognized but not yet paid is included in other liabilities on the consolidated balance sheets. Financing Obligation In March 2017, the Company entered into an agreement to lease the Minnesota facility. The Lease Agreement has an initial term of fifteen years, with four consecutive renewal options of five years each at the Company's option. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Minnesota facility as a financing transaction where the assets remain on the Company's balance sheet and a financing obligation was recorded for $20,944. As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet. Revenue Recognition The Company sells the majority of its products via direct shipment to hospitals or clinics. The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the sales price is fixed or determinable; and collectability is reasonably assured. Revenue recognition may occur upon shipment or upon delivery to the customer site, based on the contract terms. The Company records estimated sales returns, discounts and rebates as a reduction of net sales. Costs related to products delivered are recognized in the period the revenue is recognized. Cost of goods sold consists primarily of raw materials, direct labor, and manufacturing overhead. Warranty Costs The Company provides its customers with the right to receive a replacement if a product is determined to be defective at the time of shipment. Warranty reserve provisions are estimated based on Company experience, volume, and expected warranty claims. Warranty reserve, provisions and claims were as follows: Amount Balances at June 30, 2014 $ 116 Provision 377 Claims (367 ) Balance at June 30, 2015 126 Provision 490 Claims (471 ) Balance at June 30, 2016 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 $ 517 Pump Recall In April 2017, the Company initiated a voluntary recall of one type of its saline infusion pumps. The Company is in the process of recalling and replacing approximately 900 units in customer inventory and recorded a reserve for approximately $1,535 of expenses during the year ended June 30, 2017, that included $1,378 of estimated costs related to the recall and replacement of all affected saline infusion pumps, accrued consulting fees, as well as an inventory reserve for pumps held in its inventory. Litigation and Contingent Liabilities The Company and its operations from time to time are, and in the future may be, parties to or targets of lawsuits, claims, investigations, and proceedings, which are handled and defended in the ordinary course of business. The Company accrues a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When a single amount cannot be reasonably estimated but the cost can be estimated within a range, the Company accrues an amount based on management’s best estimate considering all facts and circumstances. The Company expenses legal costs, including those expected to be incurred in connection with a loss contingency, as incurred. Medical Device Excise Tax The Patient Protection and Affordable Care Act of 2010 imposed a medical device excise tax on medical device manufacturers on their sales in the U.S. of certain devices, which was effective January 1, 2013. The excise tax is 2.3% of the taxable base and applies to a substantial majority of the Company’s sales. Effective January 1, 2016, the excise tax was suspended until the end of 2017. For the years ended June 30, 2017 , 2016 and 2015 , the Company incurred $0 , $1,273 , and $2,731 of expense, respectively. Income Taxes Deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Developing a provision for income taxes, including the effective tax rate and the analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets. The Company’s judgment and tax strategies are subject to audit by various taxing authorities. Accounting guidance requires that accounting for uncertainty in income taxes is recognized in the financial statements. The guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. The guidance also provides rules on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Research and Development Expenses Research and development expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. Research and development expenses include employee compensation (including stock-based compensation), supplies and materials, consulting expenses, patent amortization, travel and facilities overhead. The Company also incurs significant expenses to operate clinical trials, including trial design, third-party fees, clinical site reimbursement, data management and travel expenses. Research and development expenses are expensed as incurred. Expenses associated with patent applications are capitalized and amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years . Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash balances primarily with one financial institution. These balances exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base. Marketable Securities The Company’s marketable securities consist solely of available-for-sale securities and were valued in accordance with the fair value measurement guidance discussed below. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity as accumulated other comprehensive income (loss), net of tax. Realized gains and losses, if any, are calculated on the specific identification method and are included in interest and other, net in the consolidated statements of operations. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported in equity as accumulated other comprehensive income (loss). Fair Value Measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs As of June 30, 2017 , the Company believes that the carrying amounts of its other financial instruments, including accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4 for additional information. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and these differences could be material. Stock-Based Compensation The Company has stock-based compensation plans, which include stock options, nonvested share awards, and an employee stock purchase plan. Fair value of option awards is determined using option-pricing models, fair value of nonvested share awards with market conditions is determined using the Monte Carlo simulation, and fair value of nonvested share awards that vest based upon performance or service conditions is determined by the closing market price of the Company’s stock on the date of grant. Stock-based compensation expense is recognized ratably over the requisite service period for the awards expected to vest. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company is working through an adoption plan which will include a review of customer contracts, applying the five-step model of the new standard to the customer contracts and comparing the results to the Company’s current accounting. As part of this, the Company is evaluating the method of adoption and assessing changes that might be necessary to information technology systems, processes, and internal controls to capture new data and address changes in financial reporting. Effective July 1, 2018, the Company will be revising its revenue recognition accounting policy and expanding revenue disclosures to reflect the requirements of the amended revenue recognition guidance. Because of the nature of the work that remains, at this time the Company is unable to reasonably estimate the impact of adoption on its consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” The guidance requires an entity to measure inventory within the scope of the ASU at the lower of cost and net realizable value. ASU 2015-11 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 and should be applied prospectively. Early adoption is permitted. The guidance is effective for the Company on July 1, 2017. The Company does not anticipate a material impact on its financial statements upon adoption. In November 2015, the FASB issued ASU 2015-17, “Balance Sheet Classification of Deferred Taxes.” The guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 and can be applied either prospectively or retrospectively. Early adoption is permitted. The guidance is effective for the Company on July 1, 2017. The Company does not anticipate a material impact on its financial statements upon adoption. In February 2016, the FASB issued ASU 2016-02, “Leases.” The guidance requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, and should be applied using a modified retrospective approach. Early adoption is permitted. The guidance is effective for the Company on July 1, 2019. The Company is currently evaluating the timing, method of adoption and impact of the new lease guidance on its financial statements. In March 2016, the FASB issued ASU 2016-09, “Stock Compensation.” The guidance simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, classification on the statement of cash flows, forfeitures, and statutory withholding requirements. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted and transition requirements vary based on the amendments adopted. The guidance is effective for the Company on July 1, 2017. The Company is currently evaluating the impact of the stock compensation guidance on its financial statements. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which revises guidance for the accounting for credit losses on financial instruments within its scope. The new standard introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance-sheet credit exposures. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted and should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The guidance is effective for the Company on July 1, 2020. The Company does not anticipate a material impact on its financial statements upon adoption. In May 2017, the FASB issued ASU 2017-09, “Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted. The Company does not anticipate a material impact on its financial statements upon adoption.

Selected Consolidated Financial

Selected Consolidated Financial Statement Information	12 Months Ended
	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected Consolidated Financial Statement Information	2. Selected Consolidated Financial Statement Information Accounts Receivable, Net Accounts receivable consists of the following: June 30, 2017 2016 Accounts receivable $ 29,336 $ 23,840 Less: Allowance for doubtful accounts (864 ) (712 ) Accounts receivable, net $ 28,472 $ 23,128 Inventories Inventories consist of the following: June 30, 2017 2016 Raw materials $ 7,898 $ 7,439 Work in process 1,221 1,142 Finished goods 7,778 8,859 Inventories, net $ 16,897 $ 17,440 Property and Equipment Property and equipment consists of the following: June 30, 2017 2016 Land $ 500 $ 500 Building 22,420 22,575 Equipment 16,502 14,141 Furniture 2,709 2,709 Leasehold improvements 86 86 Construction in progress 421 1,533 42,638 41,544 Less: Accumulated depreciation (12,942 ) (9,073 ) Total Property and equipment, net $ 29,696 $ 32,471 On December 29, 2016, the Company entered into a Purchase and Sale Agreement, as subsequently amended (collectively, the “Sale Agreement”), with Krishna Holdings, LLC (the “Buyer”), providing for the sale to Buyer of the Company’s headquarters facility in St. Paul, Minnesota (the “Facility”), for a cash purchase price of $21,500 . On March 30, 2017, the sale of the Facility under the Sale Agreement closed. The Company received proceeds of approximately $20,944 ( $21,500 , less $556 of transaction expenses). The net proceeds are to be used for working capital and general corporate purposes. In connection with the sale, the Company recorded an impairment charge of $158 . Under the Sale Agreement, the Company entered into a Lease Agreement (the “Lease Agreement”) with Krishna Holdings, LLC, Apex Holdings, LLC, Kashi Associates, LLC, Keva Holdings, LLC, S&V Ventures, LLC, Polo Group LLC, SPAV Holdings LLC, Star Associates LLC, and The Global Villa, LLC. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Facility as a financing transaction where the assets remain on the Company’s balance sheet. See Note 3 for further discussion on future payment obligations under the Lease Agreement. Patents, net Patents, net consist of the following: June 30, 2017 2016 Patents $ 6,056 $ 6,049 Less: Accumulated amortization (1,000 ) (1,036 ) Total Patents, net $ 5,056 $ 5,013 As of June 30, 2017 , future estimated amortization of patents is as follows: 2018 $ 198 2019 190 2020 180 2021 180 2022 180 Thereafter 4,128 $ 5,056 This future amortization expense is an estimate. Actual amounts may vary from these estimated amounts due to additional intangible asset acquisitions, approval of patents-in-process, potential impairment, change in useful life or other events. Accrued Expenses Accrued expenses consist of the following: June 30, 2017 2016 Salaries and bonus $ 8,247 $ 4,305 Commissions 8,217 7,788 Accrued vacation 3,436 3,498 Accrued excise, sales and other taxes 3,497 3,372 Accrued litigation 2,600 — Legal settlement 1,814 3,872 Clinical studies 657 1,757 Restructuring 169 1,337 Other accrued expenses 1,599 1,064 Total Accrued expenses $ 30,236 $ 26,993 Legal Settlement On June 28, 2016, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with the United States of America, acting through the Department of Justice (the “DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human Services, and Travis Thams, to resolve the investigation by the DOJ and the Civil Action underlying such investigation. Under the Settlement Agreement, the Company agreed to pay $8,000 (the “Settlement Amount”), as follows: an initial payment of $3,000 , paid on July 1, 2016, with the remaining $5,000 , which bears interest at 1.8% per annum, payable in 11 equal quarterly installments, beginning January 1, 2017. The amount payable within the next twelve months is included in accrued expenses (as noted in the table above) with the long-term portion included in other liabilities (as noted in the table below). Under the Settlement Agreement, if the Company makes a single payment in excess of $2,000 , which payment is not covered by an insurance policy, in settlement of any claims before paying the full Settlement Amount, the remaining unpaid balance of the Settlement Amount will become immediately due and payable, with interest accruing on the unpaid principal portion at an interest rate of 1.8% per annum. Restructuring On March 31, 2016, the Company announced a restructuring to reduce costs as part of its plan to progress towards profitability and positive cash flow. As a result, the Company recorded a restructuring expense of $2,364 during the year ended June 30, 2016, which was comprised of severance and other employee related costs. The following table provides information regarding the restructuring accrual: Severance Restructuring accrual at June 30, 2015 $ — Restructuring charge (1) 2,311 Cash payments (790 ) Restructuring accrual at June 30, 2016 1,521 Cash payments (1,330 ) Restructuring accrual at June 30, 2017 $ 191 (1) Excludes $55 of restructuring expense related to other employee related costs, and $(2) related to stock-based compensation modification expense. The Company anticipates that $169 of the restructuring accrual at June 30, 2017 , will be paid within the next twelve months and is therefore recorded in accrued expenses on the consolidated balance sheet. Estimated payments of $22 , representing the long-term portion of benefits, are recorded in other liabilities on the consolidated balance sheet at June 30, 2017 . The Company does not anticipate additional restructuring costs. CEO Departure On February 26, 2016, the Company’s former Chief Executive Officer (“CEO”) resigned from his positions as President and CEO of the Company and as a director of the Company. The Company and the former CEO entered into a Separation Agreement with benefits consistent with the Company’s Amended and Restated Executive Officer Severance Plan. The total expense related to the former CEO’s departure was $1,507 and was recorded in selling, general and administrative expenses for the year ended June 30, 2016. At June 30, 2017 approximately $413 of the package benefits is recorded in accrued expenses and $14 is recorded in other liabilities on the consolidated balance sheet, representing the long-term portion of the former CEO’s benefits. Other Liabilities The Company’s non-current other liabilities consist of the following: June 30, 2017 2016 Legal settlement $ 2,314 $ 4,128 Deferred compensation 519 684 Deferred grant incentive 473 486 Accrued severance 99 610 Other liabilities 74 102 Total Other liabilities $ 3,479 $ 6,010 Deferred Revenue In November 2016, the Company signed an exclusive distribution agreement with Medikit to sell its Diamondback 360 ® Coronary and Peripheral OAS in Japan. To secure exclusive distribution rights, Medikit made an upfront payment of $10,000 to the Company, which is refundable based on the occurrence of certain events during the term of the agreement. The Company has classified the upfront payment as long-term based on its expectation of when revenue will be recognized. The classification will be re-evaluated on a quarterly basis.

Debt (Notes)

Debt (Notes)	12 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	3. Debt Revolving Credit Facility On March 31, 2017, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). The Loan Agreement provides for a senior, secured revolving credit facility (the “Revolver”) of $40,000 (the “Maximum Dollar Amount”). Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver has a maturity date of March 31, 2020 and bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.25% . Interest on borrowings is due monthly and the principal balance is due at maturity. Borrowings up to $10,000 are available on a non-formula basis. Borrowings above $10,000 are based on (i) 85% of eligible domestic accounts receivable, and (ii) the lesser of 50% of eligible inventory or $5,000 , subject to adjustment as defined in Loan Agreement. Upon the Revolver’s maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. The Company will incur a fee equal to 1% of the Maximum Dollar Amount upon termination of the Loan Agreement or the Revolver for any reason prior to the maturity date, unless refinanced with SVB. The Company’s obligations under the Loan Agreement are secured by certain of the Company’s assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include the Company’s intellectual property, but the Company has agreed not to encumber its intellectual property without the consent of SVB. The Loan Agreement contains customary covenants limiting the Company’s ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of its business. In addition, the Loan Agreement contains financial covenants requiring the Company to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10,000 or (ii) minimum trailing three-month Adjusted EBITDA of $1,000 . If the Company does not comply with the various covenants under the Loan Agreement, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral. Under the Loan Agreement, the Company paid SVB a non-refundable commitment fee of $80 , which is being amortized to interest expense over the term of the Loan Agreement. The Company is required to pay a fee equal to 0.35% per annum on the unused portion of the Revolver, payable quarterly in arrears. SVB’s obligations to advance funds under the Revolver are subject to an initial collateral examination to be completed within 90 days of the effective date of the Loan Agreement. The Company is not obligated to draw any funds under the Revolver and no amounts were outstanding as of June 30, 2017 . Financing Obligation In connection with the sale of the Facility, the Company entered into an agreement to lease the Facility. The Lease Agreement has an initial term of 15 years , with four consecutive renewal options of 5 years each at the Company’s option, with a base annual rent in the first year of $1,638 and annual escalations of 3% thereafter. Rent during subsequent renewal terms will be at the then fair market rental rate. The effective interest rate is 7.89% . Future payments under the initial term of the Lease Agreement as of June 30, 2017 are as follows: 2018 $ 1,650 2019 1,699 2020 1,750 2021 1,803 2022 1,857 Thereafter 21,287 $ 30,046

Deferred Compensation

Deferred Compensation	12 Months Ended
	Jun. 30, 2017
Compensation Related Costs [Abstract]
Deferred Compensation	4. Deferred Compensation The Company offers certain members of management and highly compensated employees the opportunity to defer up to 100% of their base salary (after 401(k), payroll tax and other deductions), performance bonus and discretionary bonus and elect to receive the deferred compensation at a fixed future date of participant’s choosing. Each participant may, at the time of his or her deferral election, choose to allocate the deferred compensation into investment alternatives set by the Human Resources and Compensation Committee. The amount payable to each participant under the plan will change in value based upon the investment selected by that participant and is classified as current or long-term on the Company’s balance sheet based on the disbursement elections made by the participants. As of June 30, 2017 , $185 of the amount is included in accrued liabilities and $519 is included in other liabilities on the consolidated balance sheet. The available-for-sale marketable securities are primarily comprised of investments with a fixed income and equity investments and consist of the following: As of June 30, 2017 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Mutual funds $ 604 100 — $ 704 Total marketable securities $ 604 100 — $ 704 As of June 30, 2016 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Mutual funds $ 644 40 — $ 684 Total marketable securities $ 644 40 — $ 684 During the years ended June 30, 2017 and 2016 , there were $0 and $37 , respectively, in purchases of available-for-sale securities and $40 and $1,249 , respectively, of available-for-sale securities that were sold. There were no other-than-temporary impairments during the years ended June 30, 2017 and 2016 . During the years ended June 30, 2017 and 2016 , there was a realized gain of $6 and $70 that was recorded within interest and other, net on the consolidated statement of operations. The following tables provide information by level for the Company’s available-for-sale marketable securities that were measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2017 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 704 281 423 $ — Total marketable securities $ 704 281 423 $ — Fair Value Measurements as of June 30, 2016 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 684 425 259 $ — Total marketable securities $ 684 425 259 $ — The Company’s marketable securities classified within Level 1 are valued primarily using real-time quotes for transactions in active exchange markets. Marketable securities within Level 2 are valued using readily available pricing sources. There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the year ended June 30, 2017 . Any transfers between levels are recognized on the date of the event or when a change in circumstances causes a transfer.

Stock Options and Restricted St

Stock Options and Restricted Stock Awards	12 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Restricted Stock Awards	5. Stock Options and Restricted Stock Awards The Company maintains the 2014 Equity Incentive Plan (the “2014 Plan”) for the purpose of granting equity awards to employees and directors. The 2014 Plan was approved by the Company’s stockholders and became effective in November 2014 and was subsequently amended in May 2015. The 2014 Plan replaced the 2007 Equity Incentive Plan (the “2007 Plan”), and no further equity awards may be granted under the 2007 Plan. The Company also maintains one other terminated plan, the 2003 Stock Option Plan (the “2003 Plan”) (the 2014 Plan, the 2007 Plan, and the 2003 Plan are collectively referred to as the “Plans”). The 2014 Plan allows for the granting of up to 2,030,000 shares of common stock as approved by the board of directors or committees thereof in the form of nonqualified or incentive stock options, restricted stock awards, restricted stock unit awards, performance share awards, performance unit awards or stock appreciation rights to officers, directors, consultants and employees of the Company. Stock Options All options granted under the Plans become exercisable over periods established at the date of grant. The option exercise price is generally not less than the estimated fair market value of the Company’s common stock at the date of grant, as determined by the Company’s management and board of directors. In addition, the Company has granted nonqualified stock options to a director outside of the Plans. Stock option activity is as follows: Number of Options Weighted Average Exercise Price Options outstanding at June 30, 2014 922,809 $ 10.16 Exercised (222,937 ) $ 9.65 Options outstanding at June 30, 2015 699,872 $ 10.32 Exercised (87,817 ) $ 11.46 Forfeited or expired (5,176 ) $ 12.37 Options outstanding at June 30, 2016 606,879 $ 10.14 Exercised (519,297 ) $ 10.33 Expired (9,381 ) $ 8.83 Options outstanding at June 30, 2017 78,201 $ 9.07 As of June 30, 2017 , all options were fully vested. An employee’s vested options must be exercised at or within 90 days of termination to avoid forfeiture. The Company determined the fair value of options using the Black-Scholes option pricing model. The estimated fair value of options, including the effect of estimated forfeitures, was recognized as expense on a straight-line basis over the options’ vesting periods. There were no options granted during the years ended June 30, 2017 , 2016 or 2015 . The aggregate intrinsic value of a stock option award is the amount by which the market value of the underlying stock exceeds the exercise price of the award. The aggregate intrinsic value for vested and outstanding options at June 30, 2017 , 2016 and 2015 , was $1,811 , $4,025 and $11,286 , respectively. The total aggregate intrinsic value of options exercised during the years ended June 30, 2017 , 2016 and 2015 , was $7,955 , $417 , and $4,907 , respectively. Cash received from option exercises was $5,363 , $1,006 and $2,152 for the years ended June 30, 2017 , 2016 and 2015 , respectively. The weighted average remaining contractual life of options outstanding at June 30, 2017 was 0.71 years . Shares supporting option exercises are sourced from new share issuances. Restricted Stock The fair value of each restricted stock award was equal to the fair market value of the Company’s common stock at the date of grant. Vesting of time based restricted stock awards range from one to three years. The estimated fair value of restricted stock awards, including the effect of estimated forfeitures, is recognized on a straight-line basis over the restricted stock’s vesting period. Restricted stock award activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Outstanding at June 30, 2014 1,169,266 $ 18.96 Granted 362,072 $ 30.30 Forfeited (119,081 ) $ 21.43 Vested (569,163 ) $ 16.46 Outstanding at June 30, 2015 843,094 $ 25.16 Granted 522,415 $ 19.30 Forfeited (230,710 ) $ 24.83 Vested (487,226 ) $ 22.27 Outstanding at June 30, 2016 647,573 $ 23.24 Granted 258,346 $ 21.80 Forfeited (103,140 ) $ 22.11 Vested (316,195 ) $ 24.21 Outstanding at June 30, 2017 486,584 $ 21.26 Total fair value of time-based restricted stock that vested during fiscal 2017 , 2016 and 2015 was $7,655 , $10,851 , and $9,370 , respectively. Estimated pre-vesting forfeitures are considered in determining stock-based compensation expense. As of June 30, 2017 , 2016 and 2015 , the Company estimated its weighted average forfeiture rate at 17.1% , 17.0% and 19.2% , respectively. As of June 30, 2017 , there was approximately $7,780 of total unrecognized compensation expense, net of the effect of estimated forfeitures, related to nonvested restricted stock awards which is expected to be recognized over a weighted-average period of 2.2 years . Performance-Based Restricted Stock The Company also grants performance based restricted stock awards to certain executives and other management. Fiscal 2017 awards vest based on the Company’s total shareholder return relative to total shareholder return of the peer group (a market condition), as measured by the closing prices of the stock of the Company and its peer group for the 90 trading days preceding July 1, 2016 compared to the closing prices for the 90 trading days preceding July 1, 2019. Fiscal 2016 and fiscal 2015 awards included grants that vested based upon the achievement of certain thresholds measuring total shareholder return during periods within the fiscal year as compared to a pre-determined peer group of companies, and grants that vest based upon achievement of certain thresholds measuring annual revenue growth during the fiscal year as compared to a pre-determined peer group of companies. The aggregate maximum shares granted were as follows: Performance Measurement 2017 2016 2015 Total shareholder return 336,826 156,509 76,112 Annual revenue growth N/A 156,509 76,112 The results of the Company’s performance based restricted stock awards for fiscal 2016 and 2015 were as follows: Total Shareholder Return Annual Revenue Growth % Achievement Shares Vested % Achievement Shares Vested Fiscal 2015 69 % 26,339 200 % 76,112 Fiscal 2016 — % 0 — % 0 Performance-based restricted stock award activity is as follows: Number of Weighted Average Outstanding at June 30, 2014 107,132 $ 14.68 Granted 152,224 $ 22.03 Vested (107,132 ) $ 14.68 Outstanding at June 30, 2015 152,224 $ 22.03 Granted 313,018 $ 16.67 Forfeited (52,680 ) $ 28.64 Vested (102,451 ) $ 25.58 Outstanding at June 30, 2016 310,111 $ 16.67 Granted 336,826 $ 11.97 Forfeited (328,353 ) $ 16.41 Outstanding at June 30, 2017 318,584 $ 11.97 Total fair value of performance-based restricted stock that vested during fiscal 2017 , 2016 and 2015 was $0 , $2,621 , and $1,573 , respectively. Estimated pre-vesting forfeitures are considered in determining stock-based compensation expense. As of June 30, 2017 , there was approximately 2,743 of total unrecognized compensation expense, related to nonvested performance-based restricted stock awards, which is expected to be recognized over a weighted-average period of 2 years. Restricted Stock Units The Company grants restricted stock units to members of the Board of Directors. Restricted stock units represent the right to receive payment in the form of shares of the Company’s common stock or in cash at the Company’s option. Restricted stock unit payments would occur within 30 days following the six month anniversary of the date that the director ceases to serve on the Board or, if the restricted stock units are granted in lieu of an annual cash retainer, on the payment date selected by the director that is at least two years after the grant date. The estimated fair value of restricted stock awards is recognized on a straight-line basis over the vesting period. Restricted stock unit activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Restricted stock units outstanding at June 30, 2014 296,131 $ 10.09 Granted 41,172 $ 29.57 Converted to common stock (74,360 ) $ 11.90 Restricted stock units outstanding at June 30, 2015 262,943 $ 12.62 Granted 47,586 $ 22.27 Converted to common stock (5,713 ) $ 22.18 Restricted stock units outstanding at June 30, 2016 304,816 $ 13.95 Granted 54,064 $ 21.21 Forfeited (2,974 ) $ 21.01 Converted to common stock (6,476 ) $ 29.34 Restricted stock units outstanding at June 30, 2017 349,430 $ 14.73 Stock-Based Compensation Expense The following amounts were recognized as stock-based compensation expense in the consolidated statements of operations: Year Ended June 30, 2017 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 588 $ 101 $ — $ 689 Selling, general and administrative 6,568 1,065 1,024 8,657 Research and development 879 129 — 1,008 Total stock-based compensation expense $ 8,035 $ 1,295 $ 1,024 $ 10,354 Year Ended June 30, 2016 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 679 $ 115 $ — $ 794 Selling, general and administrative 8,215 1,167 1,000 10,382 Research and development 1,681 120 — 1,801 Total stock-based compensation expense $ 10,575 $ 1,402 $ 1,000 $ 12,977 Year Ended June 30, 2015 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 937 $ 64 $ — $ 1,001 Selling, general and administrative 10,486 825 917 12,228 Research and development 1,388 101 — 1,489 Total stock-based compensation expense $ 12,811 $ 990 $ 917 $ 14,718 Shares Available for Grant The following summarizes shares available for grant under the Company’s 2014 Plan: Shares available for grant at June 30, 2014 — Reserved 2,030,000 Granted (171,411 ) Forfeited or cancelled 5,866 Shares available for grant at June 30, 2015 1,864,455 Granted (883,019 ) Forfeited or cancelled 133,499 Shares available for grant at June 30, 2016 1,114,935 Granted (649,236 ) Forfeited or cancelled 415,700 Shares available for grant at June 30, 2017 (a) 881,399 (a) Excludes the effect of shares granted, exercised, forfeited or expired related to activity from shares granted outside of the 2014 Plan.

Employee Stock Purchase Plan

Employee Stock Purchase Plan	12 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Stock Purchase Plan	6. Employee Stock Purchase Plan The Company maintains an employee stock purchase plan (“ESPP”) that was approved by the Company’s stockholders in November 2015 (“2015 ESPP”) and replaced the previous ESPP that expired on May 31, 2016. The plan provides eligible employees the opportunity to acquire common stock in accordance with Section 423 of the Internal Revenue Code of 1986. Stock can be purchased each 6 -month period per year (twice per year). The purchase price is equal to 85% of the lower of the price at the beginning or the end of the respective period. Employees purchased 176,920 shares at an average price of $18.39 per share during the year ended June 30, 2017 . Shares reserved under the plan at June 30, 2017 totaled 1,844,370 .

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The components of the Company’s overall deferred tax assets and liabilities are as follows: June 30, 2017 2016 Deferred tax assets Stock-based compensation $ 5,107 $ 3,375 Accrued expenses 1,650 2,795 Inventories 433 382 Compensation accruals 261 254 Depreciation and amortization 409 360 Other 1,019 487 Research and development credit carryforwards 4,650 4,483 Net operating loss carryforwards 87,502 89,081 Total deferred tax assets 101,031 101,217 Valuation allowance (101,031 ) (101,217 ) Net deferred tax assets $ — $ — The Company has established valuation allowances to fully offset its deferred tax assets due to the uncertainty about the Company’s ability to generate the future taxable income necessary to realize these deferred assets, particularly in light of the Company’s historical losses. The future use of net operating loss carryforwards is dependent on the Company attaining profitable operations, and may be limited in any one year under Internal Revenue Code Section 382 due to significant ownership changes, as defined under such Section, as a result of the Company’s equity financings. A summary of the valuation allowances are as follows: Balances at June 30, 2014 $ 68,699 Additions 15,620 Balance at June 30, 2015 84,319 Additions 16,898 Balance at June 30, 2016 101,217 Reductions (186 ) Balance at June 30, 2017 $ 101,031 As of June 30, 2017 and 2016 , the Company had federal tax NOL carryforwards of approximately $239,308 and $244,214 , respectively. These NOL carryforwards are available to offset taxable income through 2036 and begin to expire in 2018. The Company also had various state NOL carryforwards available to offset future state taxable income. These state NOL carryforwards typically have the same expirations as the Company’s federal tax NOL carryforwards. Our federal net operating losses at June 30, 2017 do not include $42,097 of income tax deductions in excess of previously recorded tax benefits related to stock compensation. These additional tax deductions are not included in the net operating losses referenced above since the related tax benefit will not be recognized until the deductions reduce our income tax payable. The tax benefit of these excess deductions will be reflected as a credit to additional paid in capital when recognized. Accordingly, our deferred tax assets are reported net of the excess tax deductions for stock compensation. As of June 30, 2017 and 2016 , the Company had approximately $4,137 and $4,078 of federal research and development credit carryforwards, respectively. As of June 30, 2017 and 2016 , the Company had approximately $1,560 and $ 1,370 of state research and development credit carryforwards. The federal and state research and development credit carryforwards will expire through fiscal 2037 and 2032, respectively. As required by FASB ASC Topic 740, “Income Taxes,” the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recorded a liability relating to unrecognized tax benefits of $570 and $545 at June 30, 2017 and 2016 , respectively. Due to the Company having a full valuation allowance, this liability has been netted against the deferred tax asset. The Company recognizes interest and penalties related to uncertain tax provisions as part of the provision for income taxes. The Company has not currently reserved for any interest or penalties for such reserves due to the Company being in an NOL position. The Company does not expect to recognize any benefits from the unrecognized tax benefits within the next twelve months. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Balances at June 30, 2014 $ 458 Increases related to prior year tax positions 4 Increases related to current year tax positions 32 Balances at June 30, 2015 494 Increases related to prior year tax positions 10 Increases related to current year tax positions 41 Balance at June 30, 2016 545 Decreases related to prior year tax positions (8 ) Increases related to current year tax positions 33 Balance at June 30, 2017 $ 570 The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is potentially subject to income tax examinations by tax authorities for the tax years ended June 30, 2017, 2016, 2015, and 2014. The Company is not currently under examination by any taxing jurisdiction.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating Leases The Company leases manufacturing space, equipment and apartments under lease agreements that expire at various dates through March 2020 . Rental expenses were $656 , $1,049 , and $1,760 , for the years ended June 30, 2017 , 2016 , and 2015 , respectively. The decrease in rent expense in fiscal 2017 and 2016 relates to the completion of construction of the Company’s headquarters, which replaced space previously leased by the Company. In March 2017, the Company sold the headquarters facility and began leasing that facility. Future minimum lease payments under the agreements as of June 30, 2017 are as follows: 2018 $ 551 2019 472 2020 354 2021 — 2022 — Thereafter — $ 1,377 Employment Litigation The Company is party to Steven Babyak v. Cardiovascular Systems, Inc. , a lawsuit originally filed in the Superior Court of California, County of Los Angeles, on November 16, 2015. The plaintiff, a former Regional Sales Manager of the Company, made claims under California law relating to whistleblower retaliation; defamation; discrimination on the basis of association with protected group; harassment on the basis of sex in violation of FEHA; retaliation for exercising rights under FEHA; failure to prevent discrimination, harassment & retaliation in violation of FEHA; wrongful termination in violation of public policy; and violation of business and professions code. Following an April 2017 trial, a jury awarded the plaintiff $2,700 in compensatory damages with respect to his claims for whistleblower retaliation and wrongful termination in violation of public policy. The jury also awarded the plaintiff $22,400 in punitive damages with respect to the same claims. The Company filed post-trial motions for judgment notwithstanding the verdict and a new trial, on the grounds that this case was incorrectly decided as to liability, the compensatory and punitive damages were not appropriate and were excessive, and the Company was prevented from a fair trial by the improper exclusion of critical evidence. On June 29, 2017, the Court partially granted the Company’s motions, reducing the punitive damages award from $22,400 to $2,700 but denied the Company’s other motions. The Company believes that this case was incorrectly decided as to liability and the appropriateness and amount of any damages and the Company filed a Notice of Appeal on July 24, 2017. The Company has accrued $2,600 as of June 30, 2017 based on the estimate of the range of the loss that the Company believes is probable of occurring. However, it is reasonably possible that the ultimate loss, if the Company is not able to successfully challenge the verdict, could be materially different than the amount that the Company has recorded. The Company will continue to monitor the accrual associated with this matter each reporting period and make adjustments, if necessary, based on additional facts as they arise. The amounts are reflected in selling, general and administrative expenses on the Company’s consolidated statement of operations. Additionally, as of June 30, 2017 , the Company has recorded a receivable of $1,300 associated with its present assessment of the probable amount of insurance proceeds the Company would receive related to the claim, based on the accrued amount of loss referenced above. The Company estimates insurance receivables based on an analysis of its policies, including their exclusions, an assessment of the nature of each claim and remaining coverage, information from its insurance carrier, and the probable loss range referenced above. The Company then records an amount it has concluded is probable. Similar to the accrual pertaining to this matter, the Company will continue to assess the probable amount of insurance proceeds expected to be received in this case each reporting period and make adjustments, if necessary, based on additional facts as they arise. Stockholder Securities Litigation On February 12, 2016, a stockholder purporting to represent a class of persons who purchased the Company’s securities between September 12, 2011 and January 21, 2016 filed a lawsuit against the Company and certain of its officers in the U.S. District Court for the Central District of California, Paradis v. Cardiovascular Systems, Inc., et al. , 2:16-cv-01011 (C.D. Cal.). The lawsuit alleges that the Company made materially false and misleading statements and failed to disclose material adverse facts about the Company’s business, operational and financial performance, in violation of federal securities laws, relating to (1) alleged kickbacks to health care providers, (2) alleged off-label promotion of medical devices, and (3) alleged violations of the Food and Drug Administration’s laws and regulations in connection with the Company’s medical devices. On March 4, 2016, a second stockholder filed a similar lawsuit against the Company and certain of its officers in the U.S. District Court for the District of Minnesota, Shoemaker v. Cardiovascular Systems, Inc. et al. , 0:16-cv-00568 (D. Minn.). The plaintiffs seek unspecified monetary damages on behalf of the alleged class, interest, and attorney’s fees and costs of litigation. On April 12, 2016, four motions for appointment as lead plaintiff were filed in the Paradis action and three of the four proposed plaintiffs also filed a motion for appointment as lead plaintiff in the Shoemaker action. On April 26, 2016, the Paradis action was voluntarily dismissed by plaintiffs in favor of the Shoemaker action. That same day, the Shoemaker court entered an order appointing the City of Miami Fire Fighters’ & Police Officers’ Retirement Trust and the County Retirement Systems as Co-Lead Plaintiffs for representing the putative class. On June 28, 2016, the Co-Lead Plaintiffs filed a new complaint. The Company filed a motion to dismiss the complaint in this action on August 29, 2016. A hearing was held on the motion to dismiss on December 2, 2016. On March 29, 2017, the court granted the Company’s motion to dismiss the complaint and dismissed the plaintiffs’ amended complaint without prejudice. The court granted the plaintiffs’ request for leave to amend their complaint, and on June 27, 2017, the plaintiffs filed an amended complaint. The complaint makes similar allegations as the original complaint, namely, that the Company made materially false and misleading statements and failed to disclose material adverse facts about its business, operational and financial performance, in violation of federal securities laws, relating to alleged kickbacks to health care providers. The plaintiffs seek unspecified monetary damages on behalf of the alleged class, interest, and attorney’s fees and costs of litigation. The Company filed a motion to dismiss the amended complaint on August 11, 2017. The Company believes that this lawsuit is without merit and intends to defend itself vigorously. Other Matters In the ordinary conduct of business, the Company is subject to various lawsuits and claims covering a wide range of matters including, but not limited to, employment claims and commercial disputes. While the outcome of these matters is uncertain, the Company does not believe there are any other significant matters as of June 30, 2017 that are probable or estimable, for which the outcome is reasonably possible of having a material adverse impact on its consolidated balance sheets or statements of operations.

Interest and Other, Net

Interest and Other, Net	12 Months Ended
	Jun. 30, 2017
Other Income and Expenses [Abstract]
Interest and Other, Net	9. Other (Income) and Expense, Net Other (income) and expense, net, includes the following: Year Ended June 30, 2017 2016 2015 Interest expense $ 500 $ — $ 23 Interest income (383 ) (163 ) (63 ) Other 47 18 111 Total Other (income) and expense, net $ 164 $ (145 ) $ 71

Employee Benefits

Employee Benefits	12 Months Ended
	Jun. 30, 2017
Compensation and Retirement Disclosure [Abstract]
Employee Benefits	10. Employee Benefits The Company offers a 401(k) plan to its employees. Eligible employees may authorize up to $18 of their annual compensation as a contribution to the plan, subject to Internal Revenue Service limitations. The plan also allows eligible employees over 50 years old to contribute an additional $6 subject to Internal Revenue Service limitations. All employees must be at least 21 years of age to participate in the plan. The Company did not provide any employer matching contributions for the years ended June 30, 2017 , 2016 , and 2015 .

Earnings Per Share

Earnings Per Share	12 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share	11. Earnings Per Share The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations (in thousands except share and per share amounts): Year Ended June 30, 2017 2016 2015 Numerator Net loss $ (1,792 ) $ (56,024 ) $ (32,822 ) Denominator Weighted average common shares outstanding — basic 32,373,709 32,537,621 31,547,711 Effect of dilutive stock options (1) — — — Effect of dilutive restricted stock units (2) — — — Effect of performance-based restricted stock awards (3) — — — Weighted average common shares outstanding — diluted 32,373,709 32,537,621 31,547,711 Earnings per common share — basic and diluted $ (0.06 ) $ (1.72 ) $ (1.04 ) (1) At June 30, 2017 , 2016 , and 2015 ; 78,201 , 606,879 , and 699,872 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (2) At June 30, 2017 , 2016 , and 2015 ; 349,430 , 304,816 and 262,943 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (3) At June 30, 2017 , 318,584 performance-based restricted stock awards were outstanding. The effect of the shares that would be issued upon vesting of these awards has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Quarterly Data (Unaudited)

Quarterly Data (Unaudited)	12 Months Ended
	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data (Unaudited)	12. Quarterly Data (Unaudited) The following table sets forth the Company’s unaudited quarterly summary consolidated statements of operations in each of the quarters for the years ended June 30, 2017 and 2016 . The information for each of these quarters is unaudited and has been prepared on the same basis as the consolidated financial statements. This data should be read in conjunction with the consolidated financial statements and related notes. These operating results may not be indicative of results to be expected for any future period (amounts in thousands, except per share data). 2017 Q1 Q2 Q3 Q4 Total Net revenue $ 49,800 $ 50,043 $ 52,144 $ 52,919 $ 204,906 Gross profit $ 40,334 $ 40,880 $ 41,005 $ 43,246 $ 165,465 Net income (loss) $ (1,858 ) $ 1,043 $ (1,749 ) $ 772 $ (1,792 ) Earnings per common share - basic(1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) Earnings per common share - diluted(1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) 2016 Q1 Q2 Q3 Q4 Total Net revenue $ 43,871 $ 41,392 $ 44,461 $ 48,460 $ 178,184 Gross profit $ 35,100 $ 33,321 $ 35,736 $ 38,606 $ 142,763 Net loss $ (13,261 ) $ (15,163 ) $ (22,716 ) $ (4,884 ) $ (56,024 ) Earnings per common share (basic and diluted) (1) $ (0.41 ) $ (0.47 ) $ (0.69 ) $ (0.15 ) $ (1.72 ) (1) The summation of quarterly per share data may not equate to the calculation for the full fiscal year as quarterly calculations are performed on a discrete basis.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Company Description	Company Description Cardiovascular Systems, Inc. (the “Company”) was incorporated as Replidyne, Inc. (“Replidyne”) in Delaware in 2000 . On February 25, 2009, Replidyne completed its business combination with Cardiovascular Systems, Inc., a Minnesota corporation, in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 3, 2008. At the effective time of the merger, Replidyne changed its name to Cardiovascular Systems, Inc. The Company develops, manufactures and markets devices for the treatment of vascular diseases. The Company’s peripheral arterial disease (“PAD”) products, the Diamondback 360 ® Peripheral Orbital Atherectomy System (“OAS”) and the Stealth 360° ® Peripheral OAS, are catheter-based platforms capable of treating a broad range of plaque types, including calcified plaque, in leg arteries both above and below the knee, and address many of the limitations associated with other surgical, catheter and pharmacological treatment alternatives. These devices use smaller access sheaths that can provide procedural benefits and allow physicians to treat PAD patients in a variety of vessel sizes, including the small and tortuous vessels located below the knee through alternative access sites in the ankle and foot as well as in the groin. In October 2013, the Company received premarket approval from the U.S. Food and Drug Administration (“FDA”) to market the Diamondback 360 ® Coronary OAS as a treatment for severely calcified coronary arteries. In March 2017, the Company received approval from the FDA to market the Diamondback 360 ® Coronary OAS Micro Crown. The Coronary OAS Micro Crown is the only atherectomy device designed to treat both pilot tight, calcific lesions and treat 2.5 to 4mm vessels with a single device. The Company is currently selling only in the United States. In November 2016, the Company signed an exclusive distribution agreement with Medikit Co., Ltd. (“Medikit”) to sell its Diamondback 360 ® Coronary and Peripheral OAS in Japan. In March 2017, the Company received approval from Japan’s Ministry of Health, Labor and Welfare for its Diamondback 360 ® Coronary OAS Micro Crown. Pending reimbursement approval, Japan would become the first international market for any of the Company’s products. The Company is currently evaluating options for additional international markets to expand the coronary and peripheral opportunities.
Principles of Consolidation	Principles of Consolidation The consolidated balance sheets and statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows include the accounts of the Company and its wholly-owned subsidiary, after elimination of all intercompany transactions and accounts.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all money market funds and other investments purchased with an original maturity of three months or less to be cash and cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required. The Company maintains an allowance for doubtful accounts, which is an estimate regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Provisions for the allowance for doubtful accounts attributed to bad debt are recorded in general and administrative expenses. The following table shows the allowance for doubtful accounts activity: Amount Balances at June 30, 2014 $ 451 Provision for doubtful accounts 1,121 Write-offs (135 ) Balance at June 30, 2015 1,437 Provision for doubtful accounts 375 Write-offs (1,100 ) Balance at June 30, 2016 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 $ 864
Inventories	Inventories Inventories are stated at the lower of cost or market with cost determined on a first-in, first-out method of valuation. The establishment of inventory allowances for excess and obsolete inventories is based on estimated exposure on specific inventory items. We write down our inventories as we become aware of any situation where the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions.
Property and Equipment	Property and Equipment Property and equipment is carried at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over estimated useful lives of 40 years for the building; five to seven years for production equipment and furniture and fixtures; three years for computer equipment and software; and the shorter of their estimated useful lives or the lease term for leasehold improvements. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. All other expenditures for renewals and betterments are capitalized. The assets and related depreciation accounts are adjusted for property retirements and disposals with the resulting gains or losses included in the consolidated statement of operations.
Patents	Patents The capitalized costs incurred to obtain patents are amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years. The recoverability of capitalized patent costs is dependent upon the Company’s ability to derive revenue-producing products from such patents or the ultimate sale or licensing of such patent rights. Patent recoverability is regularly reviewed and any patents that are abandoned are written off at the time of abandonment.
Long-Lived Assets	Long-Lived Assets The Company regularly evaluates the carrying value of long-lived assets for events or changes in circumstances that indicate that the carrying amount may not be recoverable or that the remaining estimated useful life should be changed. An impairment loss is recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset’s carrying value over its fair value.
Operating Leases	Operating Leases The Company leases its Texas manufacturing facilities under an operating lease agreement. The lease contains rent escalation clauses for which the lease expense is recognized on a straight-line basis over the lease term. Rent expense that is recognized but not yet paid is included in other liabilities on the consolidated balance sheets.
Financing Obligation	Financing Obligation In March 2017, the Company entered into an agreement to lease the Minnesota facility. The Lease Agreement has an initial term of fifteen years, with four consecutive renewal options of five years each at the Company's option. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Minnesota facility as a financing transaction where the assets remain on the Company's balance sheet and a financing obligation was recorded for $20,944. As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet.
Revenue Recognition	Revenue Recognition The Company sells the majority of its products via direct shipment to hospitals or clinics. The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the sales price is fixed or determinable; and collectability is reasonably assured. Revenue recognition may occur upon shipment or upon delivery to the customer site, based on the contract terms. The Company records estimated sales returns, discounts and rebates as a reduction of net sales. Costs related to products delivered are recognized in the period the revenue is recognized. Cost of goods sold consists primarily of raw materials, direct labor, and manufacturing overhead.
Warranty Costs	Warranty Costs The Company provides its customers with the right to receive a replacement if a product is determined to be defective at the time of shipment. Warranty reserve provisions are estimated based on Company experience, volume, and expected warranty claims. Warranty reserve, provisions and claims were as follows: Amount Balances at June 30, 2014 $ 116 Provision 377 Claims (367 ) Balance at June 30, 2015 126 Provision 490 Claims (471 ) Balance at June 30, 2016 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 $ 517 Pump Recall In April 2017, the Company initiated a voluntary recall of one type of its saline infusion pumps. The Company is in the process of recalling and replacing approximately 900 units in customer inventory and recorded a reserve for approximately $1,535 of expenses during the year ended June 30, 2017, that included $1,378 of estimated costs related to the recall and replacement of all affected saline infusion pumps, accrued consulting fees, as well as an inventory reserve for pumps held in its inventory.
Litigation and Contingent Liabilities	Litigation and Contingent Liabilities The Company and its operations from time to time are, and in the future may be, parties to or targets of lawsuits, claims, investigations, and proceedings, which are handled and defended in the ordinary course of business. The Company accrues a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When a single amount cannot be reasonably estimated but the cost can be estimated within a range, the Company accrues an amount based on management’s best estimate considering all facts and circumstances. The Company expenses legal costs, including those expected to be incurred in connection with a loss contingency, as incurred.
Medical Device Excise Tax	Medical Device Excise Tax The Patient Protection and Affordable Care Act of 2010 imposed a medical device excise tax on medical device manufacturers on their sales in the U.S. of certain devices, which was effective January 1, 2013. The excise tax is 2.3% of the taxable base and applies to a substantial majority of the Company’s sales. Effective January 1, 2016, the excise tax was suspended until the end of 2017. For the years ended June 30, 2017 , 2016 and 2015 , the Company incurred $0 , $1,273 , and $2,731 of expense, respectively.
Income Taxes	Income Taxes Deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Developing a provision for income taxes, including the effective tax rate and the analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets. The Company’s judgment and tax strategies are subject to audit by various taxing authorities. Accounting guidance requires that accounting for uncertainty in income taxes is recognized in the financial statements. The guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. The guidance also provides rules on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Research and Development Expenses	Research and Development Expenses Research and development expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. Research and development expenses include employee compensation (including stock-based compensation), supplies and materials, consulting expenses, patent amortization, travel and facilities overhead. The Company also incurs significant expenses to operate clinical trials, including trial design, third-party fees, clinical site reimbursement, data management and travel expenses. Research and development expenses are expensed as incurred. Expenses associated with patent applications are capitalized and amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash balances primarily with one financial institution. These balances exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base.
Marketable Securities	Marketable Securities The Company’s marketable securities consist solely of available-for-sale securities and were valued in accordance with the fair value measurement guidance discussed below. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity as accumulated other comprehensive income (loss), net of tax. Realized gains and losses, if any, are calculated on the specific identification method and are included in interest and other, net in the consolidated statements of operations. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported in equity as accumulated other comprehensive income (loss).
Fair Value Measurements	Fair Value Measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs As of June 30, 2017 , the Company believes that the carrying amounts of its other financial instruments, including accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4 for additional information.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and these differences could be material.
Stock-Based Compensation	Stock-Based Compensation The Company has stock-based compensation plans, which include stock options, nonvested share awards, and an employee stock purchase plan. Fair value of option awards is determined using option-pricing models, fair value of nonvested share awards with market conditions is determined using the Monte Carlo simulation, and fair value of nonvested share awards that vest based upon performance or service conditions is determined by the closing market price of the Company’s stock on the date of grant. Stock-based compensation expense is recognized ratably over the requisite service period for the awards expected to vest.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company is working through an adoption plan which will include a review of customer contracts, applying the five-step model of the new standard to the customer contracts and comparing the results to the Company’s current accounting. As part of this, the Company is evaluating the method of adoption and assessing changes that might be necessary to information technology systems, processes, and internal controls to capture new data and address changes in financial reporting. Effective July 1, 2018, the Company will be revising its revenue recognition accounting policy and expanding revenue disclosures to reflect the requirements of the amended revenue recognition guidance. Because of the nature of the work that remains, at this time the Company is unable to reasonably estimate the impact of adoption on its consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” The guidance requires an entity to measure inventory within the scope of the ASU at the lower of cost and net realizable value. ASU 2015-11 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 and should be applied prospectively. Early adoption is permitted. The guidance is effective for the Company on July 1, 2017. The Company does not anticipate a material impact on its financial statements upon adoption. In November 2015, the FASB issued ASU 2015-17, “Balance Sheet Classification of Deferred Taxes.” The guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 and can be applied either prospectively or retrospectively. Early adoption is permitted. The guidance is effective for the Company on July 1, 2017. The Company does not anticipate a material impact on its financial statements upon adoption. In February 2016, the FASB issued ASU 2016-02, “Leases.” The guidance requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, and should be applied using a modified retrospective approach. Early adoption is permitted. The guidance is effective for the Company on July 1, 2019. The Company is currently evaluating the timing, method of adoption and impact of the new lease guidance on its financial statements. In March 2016, the FASB issued ASU 2016-09, “Stock Compensation.” The guidance simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, classification on the statement of cash flows, forfeitures, and statutory withholding requirements. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted and transition requirements vary based on the amendments adopted. The guidance is effective for the Company on July 1, 2017. The Company is currently evaluating the impact of the stock compensation guidance on its financial statements. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which revises guidance for the accounting for credit losses on financial instruments within its scope. The new standard introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance-sheet credit exposures. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted and should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The guidance is effective for the Company on July 1, 2020. The Company does not anticipate a material impact on its financial statements upon adoption. In May 2017, the FASB issued ASU 2017-09, “Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted. The Company does not anticipate a material impact on its financial statements upon adoption.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Allowance for doubtful accounts	Amount Balances at June 30, 2014 $ 451 Provision for doubtful accounts 1,121 Write-offs (135 ) Balance at June 30, 2015 1,437 Provision for doubtful accounts 375 Write-offs (1,100 ) Balance at June 30, 2016 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 $ 864
Warranty reserve, provisions and claims	Amount Balances at June 30, 2014 $ 116 Provision 377 Claims (367 ) Balance at June 30, 2015 126 Provision 490 Claims (471 ) Balance at June 30, 2016 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 $ 517

Selected Consolidated Financi23

Selected Consolidated Financial Statement Information (Tables)	12 Months Ended
	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Accounts receivable	June 30, 2017 2016 Accounts receivable $ 29,336 $ 23,840 Less: Allowance for doubtful accounts (864 ) (712 ) Accounts receivable, net $ 28,472 $ 23,128
Inventories	June 30, 2017 2016 Raw materials $ 7,898 $ 7,439 Work in process 1,221 1,142 Finished goods 7,778 8,859 Inventories, net $ 16,897 $ 17,440
Property and equipment	June 30, 2017 2016 Land $ 500 $ 500 Building 22,420 22,575 Equipment 16,502 14,141 Furniture 2,709 2,709 Leasehold improvements 86 86 Construction in progress 421 1,533 42,638 41,544 Less: Accumulated depreciation (12,942 ) (9,073 ) Total Property and equipment, net $ 29,696 $ 32,471
Patents, net	June 30, 2017 2016 Patents $ 6,056 $ 6,049 Less: Accumulated amortization (1,000 ) (1,036 ) Total Patents, net $ 5,056 $ 5,013
Patent amortization schedule	As of June 30, 2017 , future estimated amortization of patents is as follows: 2018 $ 198 2019 190 2020 180 2021 180 2022 180 Thereafter 4,128 $ 5,056
Accrued expenses	June 30, 2017 2016 Salaries and bonus $ 8,247 $ 4,305 Commissions 8,217 7,788 Accrued vacation 3,436 3,498 Accrued excise, sales and other taxes 3,497 3,372 Accrued litigation 2,600 — Legal settlement 1,814 3,872 Clinical studies 657 1,757 Restructuring 169 1,337 Other accrued expenses 1,599 1,064 Total Accrued expenses $ 30,236 $ 26,993
Restructuring accrual	Severance Restructuring accrual at June 30, 2015 $ — Restructuring charge (1) 2,311 Cash payments (790 ) Restructuring accrual at June 30, 2016 1,521 Cash payments (1,330 ) Restructuring accrual at June 30, 2017 $ 191 (1) Excludes $55 of restructuring expense related to other employee related costs, and $(2) related to stock-based compensation modification expense.
Non-current other liabilities	June 30, 2017 2016 Legal settlement $ 2,314 $ 4,128 Deferred compensation 519 684 Deferred grant incentive 473 486 Accrued severance 99 610 Other liabilities 74 102 Total Other liabilities $ 3,479 $ 6,010

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	2018 $ 1,650 2019 1,699 2020 1,750 2021 1,803 2022 1,857 Thereafter 21,287 $ 30,046

Deferred Compensation (Tables)

Deferred Compensation (Tables)	12 Months Ended
	Jun. 30, 2017
Compensation Related Costs [Abstract]
Schedule of investments	As of June 30, 2017 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Mutual funds $ 604 100 — $ 704 Total marketable securities $ 604 100 — $ 704 As of June 30, 2016 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Mutual funds $ 644 40 — $ 684 Total marketable securities $ 644 40 — $ 684
Available-for-sale marketable securities at fair value on recurring basis	Fair Value Measurements as of June 30, 2017 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 704 281 423 $ — Total marketable securities $ 704 281 423 $ — Fair Value Measurements as of June 30, 2016 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 684 425 259 $ — Total marketable securities $ 684 425 259 $ —

Stock Options and Restricted 26

Stock Options and Restricted Stock Awards (Tables)	12 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock option activity	Number of Options Weighted Average Exercise Price Options outstanding at June 30, 2014 922,809 $ 10.16 Exercised (222,937 ) $ 9.65 Options outstanding at June 30, 2015 699,872 $ 10.32 Exercised (87,817 ) $ 11.46 Forfeited or expired (5,176 ) $ 12.37 Options outstanding at June 30, 2016 606,879 $ 10.14 Exercised (519,297 ) $ 10.33 Expired (9,381 ) $ 8.83 Options outstanding at June 30, 2017 78,201 $ 9.07
Restricted stock award activity	Number of Shares Weighted Average Grant Date Fair Value Outstanding at June 30, 2014 1,169,266 $ 18.96 Granted 362,072 $ 30.30 Forfeited (119,081 ) $ 21.43 Vested (569,163 ) $ 16.46 Outstanding at June 30, 2015 843,094 $ 25.16 Granted 522,415 $ 19.30 Forfeited (230,710 ) $ 24.83 Vested (487,226 ) $ 22.27 Outstanding at June 30, 2016 647,573 $ 23.24 Granted 258,346 $ 21.80 Forfeited (103,140 ) $ 22.11 Vested (316,195 ) $ 24.21 Outstanding at June 30, 2017 486,584 $ 21.26
Aggregate maximum performance-based restricted stock awards granted	Performance Measurement 2017 2016 2015 Total shareholder return 336,826 156,509 76,112 Annual revenue growth N/A 156,509 76,112
Performance-based restricted stock award achievement	Total Shareholder Return Annual Revenue Growth % Achievement Shares Vested % Achievement Shares Vested Fiscal 2015 69 % 26,339 200 % 76,112 Fiscal 2016 — % 0 — % 0
Performance-based restricted stock award activity	Number of Weighted Average Outstanding at June 30, 2014 107,132 $ 14.68 Granted 152,224 $ 22.03 Vested (107,132 ) $ 14.68 Outstanding at June 30, 2015 152,224 $ 22.03 Granted 313,018 $ 16.67 Forfeited (52,680 ) $ 28.64 Vested (102,451 ) $ 25.58 Outstanding at June 30, 2016 310,111 $ 16.67 Granted 336,826 $ 11.97 Forfeited (328,353 ) $ 16.41 Outstanding at June 30, 2017 318,584 $ 11.97
Restricted stock unit activity	Number of Shares Weighted Average Grant Date Fair Value Restricted stock units outstanding at June 30, 2014 296,131 $ 10.09 Granted 41,172 $ 29.57 Converted to common stock (74,360 ) $ 11.90 Restricted stock units outstanding at June 30, 2015 262,943 $ 12.62 Granted 47,586 $ 22.27 Converted to common stock (5,713 ) $ 22.18 Restricted stock units outstanding at June 30, 2016 304,816 $ 13.95 Granted 54,064 $ 21.21 Forfeited (2,974 ) $ 21.01 Converted to common stock (6,476 ) $ 29.34 Restricted stock units outstanding at June 30, 2017 349,430 $ 14.73
Stock-based compensation expense	Year Ended June 30, 2017 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 588 $ 101 $ — $ 689 Selling, general and administrative 6,568 1,065 1,024 8,657 Research and development 879 129 — 1,008 Total stock-based compensation expense $ 8,035 $ 1,295 $ 1,024 $ 10,354 Year Ended June 30, 2016 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 679 $ 115 $ — $ 794 Selling, general and administrative 8,215 1,167 1,000 10,382 Research and development 1,681 120 — 1,801 Total stock-based compensation expense $ 10,575 $ 1,402 $ 1,000 $ 12,977 Year Ended June 30, 2015 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 937 $ 64 $ — $ 1,001 Selling, general and administrative 10,486 825 917 12,228 Research and development 1,388 101 — 1,489 Total stock-based compensation expense $ 12,811 $ 990 $ 917 $ 14,718
Shares available for grant	Shares available for grant at June 30, 2014 — Reserved 2,030,000 Granted (171,411 ) Forfeited or cancelled 5,866 Shares available for grant at June 30, 2015 1,864,455 Granted (883,019 ) Forfeited or cancelled 133,499 Shares available for grant at June 30, 2016 1,114,935 Granted (649,236 ) Forfeited or cancelled 415,700 Shares available for grant at June 30, 2017 (a) 881,399 (a) Excludes the effect of shares granted, exercised, forfeited or expired related to activity from shares granted outside of the 2014 Plan.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Deferred tax assets and liabilities	June 30, 2017 2016 Deferred tax assets Stock-based compensation $ 5,107 $ 3,375 Accrued expenses 1,650 2,795 Inventories 433 382 Compensation accruals 261 254 Depreciation and amortization 409 360 Other 1,019 487 Research and development credit carryforwards 4,650 4,483 Net operating loss carryforwards 87,502 89,081 Total deferred tax assets 101,031 101,217 Valuation allowance (101,031 ) (101,217 ) Net deferred tax assets $ — $ —
Summary of valuation allowances	Balances at June 30, 2014 $ 68,699 Additions 15,620 Balance at June 30, 2015 84,319 Additions 16,898 Balance at June 30, 2016 101,217 Reductions (186 ) Balance at June 30, 2017 $ 101,031
Reconciliation of beginning and ending amount of unrecognized tax benefits	Balances at June 30, 2014 $ 458 Increases related to prior year tax positions 4 Increases related to current year tax positions 32 Balances at June 30, 2015 494 Increases related to prior year tax positions 10 Increases related to current year tax positions 41 Balance at June 30, 2016 545 Decreases related to prior year tax positions (8 ) Increases related to current year tax positions 33 Balance at June 30, 2017 $ 570

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments	2018 $ 551 2019 472 2020 354 2021 — 2022 — Thereafter — $ 1,377

Interest and Other, Net (Tables

Interest and Other, Net (Tables)	12 Months Ended
	Jun. 30, 2017
Other Income and Expenses [Abstract]
Interest and other, net	Year Ended June 30, 2017 2016 2015 Interest expense $ 500 $ — $ 23 Interest income (383 ) (163 ) (63 ) Other 47 18 111 Total Other (income) and expense, net $ 164 $ (145 ) $ 71

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations	Year Ended June 30, 2017 2016 2015 Numerator Net loss $ (1,792 ) $ (56,024 ) $ (32,822 ) Denominator Weighted average common shares outstanding — basic 32,373,709 32,537,621 31,547,711 Effect of dilutive stock options (1) — — — Effect of dilutive restricted stock units (2) — — — Effect of performance-based restricted stock awards (3) — — — Weighted average common shares outstanding — diluted 32,373,709 32,537,621 31,547,711 Earnings per common share — basic and diluted $ (0.06 ) $ (1.72 ) $ (1.04 ) (1) At June 30, 2017 , 2016 , and 2015 ; 78,201 , 606,879 , and 699,872 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (2) At June 30, 2017 , 2016 , and 2015 ; 349,430 , 304,816 and 262,943 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (3) At June 30, 2017 , 318,584 performance-based restricted stock awards were outstanding. The effect of the shares that would be issued upon vesting of these awards has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Quarterly Data (Unaudited) (Tab

Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of quarterly financial information	2017 Q1 Q2 Q3 Q4 Total Net revenue $ 49,800 $ 50,043 $ 52,144 $ 52,919 $ 204,906 Gross profit $ 40,334 $ 40,880 $ 41,005 $ 43,246 $ 165,465 Net income (loss) $ (1,858 ) $ 1,043 $ (1,749 ) $ 772 $ (1,792 ) Earnings per common share - basic(1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) Earnings per common share - diluted(1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) 2016 Q1 Q2 Q3 Q4 Total Net revenue $ 43,871 $ 41,392 $ 44,461 $ 48,460 $ 178,184 Gross profit $ 35,100 $ 33,321 $ 35,736 $ 38,606 $ 142,763 Net loss $ (13,261 ) $ (15,163 ) $ (22,716 ) $ (4,884 ) $ (56,024 ) Earnings per common share (basic and diluted) (1) $ (0.41 ) $ (0.47 ) $ (0.69 ) $ (0.15 ) $ (1.72 ) (1) The summation of quarterly per share data may not equate to the calculation for the full fiscal year as quarterly calculations are performed on a discrete basis.

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Jun. 30, 2017USD ($)financial_institution	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Accounting Policies [Abstract]
Entity incorporation, state name	Delaware
Entity incorporation, year of incorporation	2,000
Accounts receivable credit period	30 days
Property and Equipment and Patents [Line Items]
Medical Device Excise Tax, percentage	2.30%
Medical Device Excise Tax | $	$ 0	$ 1,273	$ 2,731
Number of financial institutions the company maintains its cash balances | financial_institution	1
Building
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	40 years
Computer Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	3 years
Minimum | Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	5 years
Maximum
Property and Equipment and Patents [Line Items]
Patent amortization tenure	20 years
Maximum | Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	7 years

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Allowance for Doubtful Accounts Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Allowance for doubtful accounts activity
Beginning balance	$ 712	$ 1,437	$ 451
Provision for doubtful accounts	465	375	1,121
Write-offs	(313)	(1,100)	(135)
Ending balance	$ 864	$ 712	$ 1,437

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Warranty Reserve) (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2017units	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Warranty reserve, provisions and claims
Beginning balance		$ 145	$ 126	$ 116
Provision		1,733	490	377
Claims		(1,361)	(471)	(367)
Ending balance		517	$ 145	$ 126
Pump recall disclosures
Number of recalled pumps | units	900
Recall expense, inventory reserve		1,535
Recall replacement costs and reserves		$ 1,378

Selected Consolidated Financi35

Selected Consolidated Financial Statement Information (Accounts Receivable, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Accounts receivable	$ 29,336	$ 23,840
Less: Allowance for doubtful accounts	(864)	(712)
Accounts receivable, net	$ 28,472	$ 23,128

Selected Consolidated Financi36

Selected Consolidated Financial Statement Information (Inventories) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Raw materials	$ 7,898	$ 7,439
Work in process	1,221	1,142
Finished goods	7,778	8,859
Inventories, net	$ 16,897	$ 17,440

Selected Consolidated Financi37

Selected Consolidated Financial Statement Information (Property and Equipment) (Details) - USD ($) $ in Thousands	Mar. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Total Property and equipment		$ 42,638	$ 41,544
Less: Accumulated depreciation		(12,942)	(9,073)
Total Property and equipment, net		29,696	32,471
Sale Agreement
Facility Purchase Price	$ 21,500
Net Proceeds on Sale of the Facility	20,944
Transaction Costs, Sale Leaseback	556
Gain (Loss) on Sale of Assets and Asset Impairment Charges	$ 158
Land
Property, Plant and Equipment [Line Items]
Total Property and equipment		500	500
Building
Property, Plant and Equipment [Line Items]
Total Property and equipment		22,420	22,575
Equipment
Property, Plant and Equipment [Line Items]
Total Property and equipment		16,502	14,141
Furniture
Property, Plant and Equipment [Line Items]
Total Property and equipment		2,709	2,709
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total Property and equipment		86	86
Construction in progress
Property, Plant and Equipment [Line Items]
Total Property and equipment		$ 421	$ 1,533

Selected Consolidated Financi38

Selected Consolidated Financial Statement Information (Patents, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Patents	$ 6,056	$ 6,049
Less: Accumulated amortization	(1,000)	(1,036)
Total Patents	$ 5,056	$ 5,013

Selected Consolidated Financi39

Selected Consolidated Financial Statement Information (Estimated Amortization of Patents) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Estimated amortization of patents and patent licenses
2,017	$ 198
2,018	190
2,019	180
2,020	180
2,021	180
Thereafter	4,128
Total Patents	$ 5,056	$ 5,013

Selected Consolidated Financi40

Selected Consolidated Financial Statement Information (Accrued Expenses) (Details) $ in Thousands	Jun. 28, 2016USD ($)installment_paymentRate	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)
Accrued expenses
Salaries and bonus		$ 8,247	$ 4,305
Commissions		8,217	7,788
Accrued vacation		3,436	3,498
Accrued excise, sales and other taxes		3,497	3,372
Accrued litigation		2,600	0
Clinical studies		657	1,757
Legal settlement		1,814	3,872
Restructuring		169	1,337
Other accrued expenses		1,599	1,064
Total Accrued expenses		$ 30,236	$ 26,993
Legal settlement
Litigation Settlement, Amount	$ 8,000
Payments for Legal Settlements	3,000
Settlement Payable in Installments	$ 5,000
Litigation Settlement Interest, Percentage | Rate	0.00%
Litigation Settlement, Number of Quarterly Installment Payment | installment_payment	11
Single payment threshold amount	$ 2,000

Selected Consolidated Financi41

Selected Consolidated Financial Statement Information (Restructuring Accrual) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Restructuring Cost and Reserve [Line Items]
Document Period End Date	Jun. 30, 2017
Restructuring accrual to be paid within the next twelve months	$ 169	$ 1,337
Restructuring accrual
Restructuring charge	0	2,364	$ 0
Accrued Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring accrual to be paid within the next twelve months	169
Other Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring accrual, long-term portion	22
Employee Severance
Restructuring accrual
Balance at beginning of period	1,521	0
Restructuring charge		2,311
Cash payments	(1,330)	(790)
Balance at end of period	191	1,521	$ 0
Employee Severance | Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Severance Costs		$ 1,507
Employee Severance | Accrued Expenses
Restructuring Cost and Reserve [Line Items]
Accrued Liabilities	413
Employee Severance | Other Liabilities
Restructuring Cost and Reserve [Line Items]
Accrued Liabilities	14
Other Employee Related Costs
Restructuring accrual
Restructuring charge	55
Stock-based Modification Expense
Restructuring accrual
Restructuring charge	$ (2)

Selected Consolidated Financi42

Selected Consolidated Financial Statement Information (Other Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Legal settlement	$ 2,314	$ 4,128
Deferred compensation	519	684
Deferred grant incentive	473	486
Accrued severance	99	610
Other liabilities	74	102
Total Other liabilities	$ 3,479	$ 6,010

Selected Consolidated Financi43

Selected Consolidated Financial Statement Information (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring accrual to be paid within the next twelve months	$ 169	$ 1,337
Accrued Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring accrual to be paid within the next twelve months	$ 169

Selected Consolidated Financi44

Selected Consolidated Financial Statement Information Deferred Revenue (Details) $ in Thousands	1 Months Ended
	Nov. 30, 2016USD ($)
Quarterly Financial Information Disclosure [Abstract]
Deferred revenue	$ 10,000

Debt (Revolving Credit Facility

Debt (Revolving Credit Facility) (Details) - Revolving Credit Facility [Member] - Silicon Valley Bank [Member] - USD ($)	Mar. 31, 2017	Jun. 30, 2017
Debt Instrument [Line Items]
Percentage of Eligible Accounts Receivable	85.00%
Maximum [Member]
Debt Instrument [Line Items]
Borrowings Available On A Formula Basis	$ 10,000,000
Prime Rate [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 40,000,000
Line of Credit Facility, Expiration Date	Mar. 31, 2020
Percent Reduction to Prime Interest Rate	0.25%
Percent of Eligible Inventory	50.00%
Maximum Eligible Inventory Value	$ 5,000,000
Early Termination Fee	1.00%
Covenant, Minimum Unused Availability	$ 10,000,000
Covenant, Adjusted EBITDA	$ 1,000,000
Interest Rate Increase For Noncompliance	5.00%
Line of Credit Facility, Commitment Fee Amount	$ 80,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.00%
Number of Days for Collateral Examination	90 days
Line of Credit Facility, Fair Value of Amount Outstanding		$ 0

Debt (Financing Obligation) (De

Debt (Financing Obligation) (Details) - Financing Obligation [Member] $ in Thousands	3 Months Ended
	Jun. 30, 2017USD ($)optionsRate
Capital Lease Obligations
Capital lease term of contract (in years)	15 years
Capital lease number of renewal options | options	4
Capital lease term of renewal (in years)	5 years
Annual base rent	$ 1,638
Annual interest rate escalations (as a percent) | Rate	3.00%
Effective interest rate (as a percent) | Rate	7.89%
Capital Leases, Future Payments
Capital Leases, Future Minimum Payments Due, Next Twelve Months	$ 1,650
Capital Leases, Future Minimum Payments Due in Two Years	1,699
Capital Leases, Future Minimum Payments Due in Three Years	1,750
Capital Leases, Future Minimum Payments Due in Four Years	1,803
Capital Leases, Future Minimum Payments Due in Five Years	1,857
Capital Leases, Future Minimum Payments Due Thereafter	21,287
Capital Leases, Future Minimum Payments Due	$ 30,046

Deferred Compensation (Details

Deferred Compensation (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Purchases of available-for-sale securities	$ 0	$ 37,000	$ 2,112,000
Sale of available-for-sale securities	40,000	1,249,000
Other-than-temporary impairments	0	0
Interest and Other, Net
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Realized gain	6,000	$ 70,000
Accrued Expenses
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation payable, current	185,000
Other Liabilities
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation payable, current	$ 519,000
Maximum
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation, percentage of base salary	100.00%

Deferred Compensation (Investme

Deferred Compensation (Investments) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Investment [Line Items]
Amortized Cost	$ 604	$ 644
Unrealized Gains	100	40
Unrealized Losses	0	0
Fair Value	704	684
Mutual funds
Investment [Line Items]
Amortized Cost	604	644
Unrealized Gains	100	40
Unrealized Losses	0	0
Fair Value	$ 704	$ 684

Deferred Compensation (Availabl

Deferred Compensation (Available-for-sale Securities on Recurring Basis) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Document Period End Date	Jun. 30, 2017
Total marketable securities	$ 704,000	$ 684,000
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	0
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount	0
Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	704,000	684,000
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	704,000	684,000
Recurring | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	704,000	684,000
Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	281,000	425,000
Recurring | Level 1 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	281,000	425,000
Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	423,000	259,000
Recurring | Level 2 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	423,000	259,000
Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	0	0
Recurring | Level 3 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	0	$ 0
Other Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation payable, current	$ 519,000

Stock Options and Restricted 50

Stock Options and Restricted Stock Awards (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested options granted to employees after termination	90 days
Options granted	0	0	0
Aggregate intrinsic value for vested and outstanding options	$ 1,811,000	$ 4,025,000	$ 11,286,000
Total aggregate intrinsic value of options exercised	7,955,000	417,000	4,907,000
Cash received from option exercises	$ 5,363,000	$ 1,006,000	$ 2,152,000
Weighted-average contractual life of options outstanding	8 months 16 days
Forfeiture rate	17.10%	17.00%	19.20%
Total compensation cost for non-vested awards not yet recognized	$ 7,780,000
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of vested stocks	$ 7,655,000	$ 10,851,000	$ 9,370,000
Weighted-average period expected to recognize nonvested awards	2 years 2 months 12 days
Restricted Stock Awards | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of vested stocks	$ 0	$ 2,621,000	$ 1,573,000
Total compensation cost for non-vested awards not yet recognized	$ 2,743
Weighted-average period expected to recognize nonvested awards	2 years
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum period for payment on restricted stock unit following the six month anniversary date	30 days
Minimum period after grant date	2 years
the 2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock approved	2,030,000

Stock Options and Restricted 51

Stock Options and Restricted Stock Awards (Stock Option Activity) (Details) - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Number of Options
Beginning balance (in shares)	606,879	699,872	922,809
Exercised (in shares)	(519,297)	(87,817)	(222,937)
Expired (in shares)	(9,381)	(5,176)
Ending balance (in shares)	78,201	606,879	699,872
Weighted Average Exercise Price
Beginning balance (in usd per share)	$ 10.14	$ 10.32	$ 10.16
Exercised (in usd per share)	10.33	11.46	9.65
Expired (in usd per share)	8.83	12.37
Ending balance (in usd per share)	$ 9.07	$ 10.14	$ 10.32

Stock Options and Restricted 52

Stock Options and Restricted Stock Awards (Restricted Stock) (Details) - Restricted Stock - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Number of Shares
Outstanding at beginning of period (in shares)	647,573	843,094	1,169,266
Granted (in shares)	258,346	522,415	362,072
Forfeited (in shares)	(103,140)	(230,710)	(119,081)
Vested (in shares)	(316,195)	(487,226)	(569,163)
Outstanding at end of period (in shares)	486,584	647,573	843,094
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 23.24	$ 25.16	$ 18.96
Forfeited (in usd per share)	22.11	24.83	21.43
Granted (in usd per share)	21.80	19.30	30.30
Vested (in usd per share)	24.21	22.27	16.46
Outstanding at end of period (in usd per share)	$ 21.26	$ 23.24	$ 25.16

Stock Options and Restricted 53

Stock Options and Restricted Stock Awards (Maximum Performance Shares Granted) (Details) - Performance Shares - shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)	336,826	313,018	152,224
Total Shareholder Return
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)	336,826	156,509	76,112
Annual Revenue Growth
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)		156,509	76,112

Stock Options and Restricted 54

Stock Options and Restricted Stock Awards (Performance Based Restricted Stock Awards) (Details) - Performance Shares - shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)	102,451	107,132
Total Shareholder Return
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
% Achievement	0.00%	69.00%
Vested (in shares)	0	26,339
Annual Revenue Growth
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
% Achievement	0.00%	200.00%
Vested (in shares)	0	76,112

Stock Options and Restricted 55

Stock Options and Restricted Stock Awards (Performace-based Restricted Stock Award Activity) (Details) - Performance Shares - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Number of Shares
Outstanding at beginning of period (in shares)	310,111	152,224	107,132
Granted (in shares)	336,826	313,018	152,224
Vested (in shares)		(102,451)	(107,132)
Forfeited (in shares)	(328,353)	(52,680)
Outstanding at end of period (in shares)	318,584	310,111	152,224
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 16.67	$ 22.03	$ 14.68
Granted (in usd per share)	11.97	16.67	22.03
Vested (in usd per share)		25.58	14.68
Forfeited (in usd per share)	16.41	28.64
Outstanding at end of period (in usd per share)	$ 11.97	$ 16.67	$ 22.03

Stock Options and Restricted 56

Stock Options and Restricted Stock Awards (Restricted Stock Unit Activity) (Details) - Restricted Stock Units - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Number of Shares
Outstanding at beginning of period (in shares)	304,816	262,943	296,131
Granted (in shares)	54,064	47,586	41,172
Forfeited (in shares)	(2,974)
Converted to common stock (in shares)	(6,476)	(5,713)	(74,360)
Outstanding at end of period (in shares)	349,430	304,816	262,943
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 13.95	$ 12.62	$ 10.09
Granted (in usd per share)	21.21	22.27	29.57
Forfeited (in usd per share)	21.01
Converted to common stock	29.34	22.18	11.90
Outstanding at end of period (in usd per share)	$ 14.73	$ 13.95	$ 12.62

Stock Options and Restricted 57

Stock Options and Restricted Stock Awards (Stock-based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 10,354	$ 12,977	$ 14,718
Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	8,035	10,575	12,811
Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,295	1,402	990
Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,024	1,000	917
Cost of goods sold
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	689	794	1,001
Cost of goods sold | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	588	679	937
Cost of goods sold | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	101	115	64
Cost of goods sold | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0	0	0
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	8,657	10,382	12,228
Selling, general and administrative | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	6,568	8,215	10,486
Selling, general and administrative | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,065	1,167	825
Selling, general and administrative | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,024	1,000	917
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,008	1,801	1,489
Research and development | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	879	1,681	1,388
Research and development | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	129	120	101
Research and development | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 0	$ 0	$ 0

Stock Options and Restricted 58

Stock Options and Restricted Stock Awards (Shares Available for Grant) (Details) - shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Shares available for grant
Beginning balance (in shares)	1,114,935	1,864,455	0
Reserved (in shares)			2,030,000
Granted (in shares)	(649,236)	(883,019)	(171,411)
Forfeited or cancelled (in shares)	415,700	133,499	5,866
Ending balance (in shares)	881,399	1,114,935	1,864,455

Employee Stock Purchase Plan (D

Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan	12 Months Ended
	Jun. 30, 2017$ / sharesshares
Schedule of Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]
Stock purchase period	6 months
Purchase price of stock in percentage	85.00%
Number of shares purchased by employee	176,920
Average price of share purchased by employee | $ / shares	$ 18.39
Shares of common stock reserved under the ESPP	1,844,370

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Deferred tax assets
Stock-based compensation	$ 5,107	$ 3,375
Accrued expenses	1,650	2,795
Inventories	433	382
Compensation accruals	261	254
Depreciation and amortization	409	360
Other	1,019	487
Research and development credit carryforwards	4,650	4,483
Net operating loss carryforwards	87,502	89,081
Total deferred tax assets	101,031	101,217
Valuation allowance	(101,031)	(101,217)	$ (84,319)	$ (68,699)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Valuation Allowan

Income Taxes (Valuation Allowance) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Summary of valuation allowances
Beginning balance	$ 101,217	$ 84,319	$ 68,699
Additions	(186)	16,898	15,620
Ending balance	$ 101,031	$ 101,217	$ 84,319

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Operating Loss Carryforwards [Line Items]
Liability relating to unrecognized tax benefits	$ 570	$ 545	$ 494	$ 458
Federal
Operating Loss Carryforwards [Line Items]
Tax NOL carryforwards	239,308	244,214
Income tax deductions in excess of tax benefits related to stock compensation	42,097
Research and development credit carryforwards	4,137	4,078
State
Operating Loss Carryforwards [Line Items]
Research and development credit carryforwards	$ 1,560	$ 1,370

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Reconciliation of beginning and ending amount of unrecognized tax benefits
Beginning balance	$ 545	$ 494	$ 458
Increases related to prior year tax positions		10	4
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	(8)
Increases related to current year tax positions	(33)	(41)	(32)
Ending balance	$ 570	$ 545	$ 494

Commitments and Contingencies64

Commitments and Contingencies (Operating Leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Rental expenses	$ 656	$ 1,049	$ 1,760
Operating Leases, Future Minimum Payments Receivable [Abstract]
2,018	551
2,019	472
2,020	354
2,021	0
2,022	0
Thereafter	0
Total	$ 1,377

Commitments and Contingencies65

Commitments and Contingencies (Litigation) (Details) $ in Thousands	Jun. 29, 2017USD ($)	Apr. 12, 2016plaintiff	Apr. 30, 2017USD ($)	Jun. 30, 2017USD ($)
Babyak Action
Loss Contingencies [Line Items]
Compensatory damages awarded			$ 2,700
Punitive damages awarded	$ 2,700		$ 22,400
Loss contingency accrual				$ 2,600
Loss contingency, insurance proceeds receivable				$ 1,300
Paradis Action | Pending Litigation
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff		4
Paradis and Shoemaker Action | Pending Litigation
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff		3

Interest and Other, Net (Detail

Interest and Other, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Other Income and Expenses [Abstract]
Interest expense	$ 500	$ 0	$ 23
Interest income	(383)	(163)	(63)
Other	47	18	111
Total Other (income) and expense, net	$ 164	$ (145)	$ 71

Employee Benefits (Details)

Employee Benefits (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Contribution by employee in plan	$ 18,000
Age of eligible employees for contribute additional amount	50 years
Additional contribution by employee in plan	$ 6,000
Minimum age for qualifying in 401(a) plan	21 years
Employer matching contributions	$ 0	$ 0	$ 0

Earnings Per Share (Reconciliat

Earnings Per Share (Reconciliation of Numerators and Denominators) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Numerator
Net loss	$ 772	$ (1,749)	$ 1,043	$ (1,858)	$ (4,884)	$ (22,716)	$ (15,163)	$ (13,261)	$ (1,792)	$ (56,024)	$ (32,822)
Denominator
Weighted average common shares - basic (in shares)									32,373,709	32,537,621	31,547,711
Weighted average common shares outstanding - diluted (in shares)									32,373,709	32,537,621	31,547,711
Net loss per common share - basic and diluted (in usd per share)					$ (0.15)	$ (0.69)	$ (0.47)	$ (0.41)	$ (0.06)	$ (1.72)	$ (1.04)

Earnings Per Share (Details Tex

Earnings Per Share (Details Textual) - shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Document Period End Date	Jun. 30, 2017
Common stock, shares outstanding	32,849,563	32,792,497
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	78,201	606,879	699,872
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	349,430	304,816	262,943
Performance Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	318,584

Quarterly Data (Unaudited) (Det

Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 52,919	$ 52,144	$ 50,043	$ 49,800	$ 48,460	$ 44,461	$ 41,392	$ 43,871	$ 204,906	$ 178,184	$ 181,544
Gross profit	43,246	41,005	40,880	40,334	38,606	35,736	33,321	35,100	165,465	142,763	142,024
Net loss	$ 772	$ (1,749)	$ 1,043	$ (1,858)	$ (4,884)	$ (22,716)	$ (15,163)	$ (13,261)	$ (1,792)	$ (56,024)	$ (32,822)
Net loss per common share (basic & diluted) (in usd per share)					$ (0.15)	$ (0.69)	$ (0.47)	$ (0.41)	$ (0.06)	$ (1.72)	$ (1.04)
Earnings Per Share, Basic	$ 0.02	$ (0.05)	$ 0.03	$ (0.06)					(0.06)
Earnings Per Share, Diluted	$ 0.02	$ (0.05)	$ 0.03	$ (0.06)					$ (0.06)